Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease.
Alzheimers Dement
2025
21
10
In vivo molecular imaging of breast cancer metabolic heterogeneity using [1-13C]pyruvate-d3 hyperpolarized by reversible exchange with parahydrogen.
Theranostics
2025
15
9
3714-3723
Synthesis and Preliminary Evaluation of Novel PSMA-targeting Small Molecule Drug Conjugate Using the Highly Potent PARP inhibitor Venadarib for Treatment of Prostate Cancer
J Nucl Med
2025
66 Suppl 1
Predicting Time-Integrated Activity of [177Lu]Lu-PSMA-I&T in Kidneys Using Single-Time-Point [68Ga]Ga-PSMA-HBED-CC PET/CT and Non-Linear Mixed-Effects Modeling
J Nucl Med
2025
66 Suppl 1
The Personalized REsponse Monitoring In Oncology (PREMIO) criteria-a new set of response evaluation criteria for PET imaging, including a classification system for new lesions (mBI-RADS)
J Nucl Med
2025
66 Suppl 1
[Options in nuclear medicine for advanced prostate cancer in practice].
Radiologie (Heidelb)
2025
65
11
877-886
Elevated FDG uptake in non-tumorous lung regions does not predict immune checkpoint inhibitor-related pneumonitis in lung cancer patients.
Front Oncol
2025
15
Changes of Prostate-Specific Membrane Antigen-Radioligand Uptake on PET with Systemic Therapy in Patients with Metastatic Renal Cell Carcinoma.
Cancers (Basel)
2025
17
11
PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE - first clinical experiences.
Eur J Nucl Med Mol Imaging
2025
52
3
900-912
Pattern of Failure in Patients with Biochemical Recurrence After PSMA Radioguided Surgery.
J Nucl Med
2025
66
1
67-72